ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
ProSomnus Initiates Restructuring to Secure Financial Future
News On ProSomnus Inc. (OSA) Now Under OSAP
News On ProSomnus Inc. (OSA) Now Under OSAP
ProSomnus, Inc. Common Stock (NASDAQ:OSA) Q4 2023 Earnings Call Transcript
Prosomnus, Inc.: Navigating Market Volatility and Liquidity Risks Post-Merger
Q4 2023 Prosomnus Inc Earnings Call
Analysts Offer Insights on Healthcare Companies: ProSomnus (OSA), Merck & Company (MRK) and Phreesia (PHR)
ProSomnus Q4 Sales $7.84M Beat $7.37M Estimate
ProSomnus Q4 Sales $7.84M Beat $7.37M Estimate
Earnings Call Summary | ProSomnus(OSA.US) Q4 2023 Earnings Conference
The following is a summary of the ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript:Financial Performance:ProSomnus reported a record revenue for Q4 2023 of $7.8 million and a full-year 2023 reve
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersApollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) share
ProSomnus Reports Q4 Results
ProSomnus 4Q Rev $7.84M >OSA
ProSomnus 4Q Rev $7.84M >OSA
Press Release: ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy(TM) f
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report
Craig-Hallum Reaffirms Their Hold Rating on ProSomnus (OSA)
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced today it has postponed the release of
Top 4 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Investors Give ProSomnus, Inc. (NASDAQ:OSA) Shares A 30% Hiding
Unfortunately for some shareholders, the ProSomnus, Inc. (NASDAQ:OSA) share price has dived 30% in the last thirty days, prolonging recent pain.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced results of its pilot study for the
No Data